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Abstract
Background: Despite the rapid expansion of antiretroviral therapy services, ‘loss to follow-up’ is a significant public
health concern globally. Loss to follow-up of individuals from ART has a countless negative impact on the
treatment outcomes. There is, however, limited information about the incidence and predictors of loss to follow-up
in our study area. Thus, this study aimed to determine the incidence rate and predictors of loss to follow-up among
adult HIV patients on ART.
Methods: A retrospective cohort study was undertaken using 484 HIV patients between January 30, 2008, and
January 26, 2018, at Debre Markos Referral Hospital. All eligible HIV patients who fulfilled the inclusion criteria were
included in this study. Data were entered into Epi-data Version 4.2 and analyzed using STATATM Version 14.0
software. The Nelson-Aalen cumulative hazard estimator was used to estimate the hazard rate of loss to follow-up,
and the log-rank test was used to compare the survival curve between different categorical variables. Both
bivariable and multivariable Cox-proportional hazard regression models were fitted to identify predictors of LTFU.
Results: Among a cohort of 484 HIV patients at Debre Markos Referral Hospital, 84 (17.36%) were loss their ART
follow-up. The overall incidence rate of loss to follow-up was 3.7 (95% CI 3.0, 5.0) per 100 adult-years. The total
LTFU free time of the participants was 2294.8 person-years. In multivariable Cox-regression analysis, WHO stage IV
(AHR 2.8; 95% CI 1.2, 6.2), having no cell phone (AHR 1.9; 95% CI 1.1, 3.4), and rural residence (AHR 0.6; 95% CI 0.37,
0.99) were significant predictors of loss to follow-up.
Conclusion: The incidence of loss to ART follow-up in this study was low. Having no cell phone and WHO clinical
stage IV were causative predictors, and rural residence was the only protective factor of loss to follow-up. Therefore,
available intervention modalities should be strengthened to mitigate loss to follow-up by addressing the identified
risk factors.
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Plain English summary
Loss to follow-up is a serious public health concern
throughout the world. In Ethiopia, there is limited infor-
mation regarding incidence and predictors of loss to
follow-up amongst adult HIV patients on ART. There-
fore, this retrospective cohort study estimates the inci-
dence and predictors of loss to follow-up among adult
HIV patients on ART at Debre Markos referral hospital.
About 484 samples were included in the study. Data
analysis was carried out using STATA Version 14.0 stat-
istical software. The cox-proportional hazard regression
model was used to identify the predictors of loss to
follow-up. In this study, the incidence of loss to follow-
up in this study was high. Having no cell phone, rural
residence, and WHO clinical stage IV were the predic-
tors of loss to follow-up
Background
The acquired immunodeficiency syndrome (AIDS) pan-
demic remains the most serious of infectious disease ob-
stacles to public health [1]. On the other hand, ART
suppress the viral multiplication, and enhance the pa-
tient’s quality of life [2–4]. Since according to the World
Health Organization (WHO) 2018 and UNAIDS 2019
global HIV/AIDS epidemic report, ART had a significant
contribution to new HIV infection fell by 37% and HIV/
AIDS-related death by 45% correspondingly [5, 6]. In
addition, the risk of HIV transmission from HIV patients
who had good ART adherence with regular follow-up to
their uninfected sexual partners was dimmed drastically
by 96% [7].
Loss to follow-up (LTFU) is a significant cause for
treatment failure and threatens the enhancement of HIV
treatment outcomes among patients on ART [8]. LTFU
is defined as clients stopped ART follow-up for 3
months or longer due to different reasons [2]. At the
end of 2014, LTFU was estimated to be 18.7% in
Ethiopia, which affects ART effectiveness [9]. This indi-
cates that the expected outcome of ART is achieved
when the patients exhibit good adherence with regular
follow-up [10].
The incidence of LTFU ranged from 7.1 per 100
person-year in India [11], 10.3 per 100 person-year in
South Africa [12], and 43 per 100 person-year in Uganda
[13]. In Ethiopia, previous studies reported 8.4 per 100
person-year in Gondar Teaching Hospital [14] and 8.2 per
100 person-year in Aksum St. Marry Hospital [15]. Socio-
demographic characteristics [11, 12, 15–19], tuberculosis,
ionized prophylaxis, ART side effects, changing ART, dur-
ation on ART, viral load, CD4 count, WHO stages III &
IV, being bed-ridden, and ambulatory patient were some
of the factors associated with LTFU [12–16, 20–22].
Mortality, after loss to follow-up in African countries,
ranges from 12 to 87% [23]. LTFU also increased the risk
of HIV-related morbidity, drug resistance, hospitalization,
and the risk of transmitting drug-resistant strains and
shortened the survival status of HIV patients [2, 20, 24].
To tackle these adverse effects, scale-up of ART centers
and tracing back of patients as interventions have also
been taken from locally and globally [2, 8, 25].
Currently, the Ethiopian government targeted 90%
HIV viral load suppression rate for people on ART care
and treatment for ending the AIDS epidemic by 2020
[8]. To succeed in this plan, data related to the incidence
and predictors of LTFU are crucial. Thus, we conducted
this study to estimate the incidence and predictors of
LTFU among adult HIV patients on ART at Debre
Markos Referral Hospital. The results of this study will
inform policymakers and program planners working at
various levels of HIV/AIDS control programs.
Methods
Study design, setting, and period
A hospital-based retrospective cohort study in Debre-
Markos Referral Hospital (DMRH) at Debre Markos
Town was undertaken. Debre Markos Town is located
299 km far from Addis Ababa, the capital city of
Ethiopia, and 265 km far from Bahir-Dar, the capital city
of Amhara Regional State. Debre Markos referral hos-
pital serves more than 3.5 million people of the East
Gojjam Administrative Zone and neighboring areas.
More than twelve thousands of HIV-positive adults have
been initiated antiretroviral therapy (ART) care and
treatment in Debre Markos Referral Hospital since 2005.
As 2018 annual report, the hospital was providing ART
care and treatment services to 3716 adult HIV patients
Population
All adult HIV patients initiated on ART from January
30, 2008, to January 26, 2018, at Debre Markos Referral
Hospital in the ART clinic were our source population.
All adult HIV patients initiated on ART from January
30, 2008, to October 30, 2017, at Debre Markos Referral
Hospital in the ART clinic were our study population.
Therefore, those adult HIV patients who had at least 1-
month follow-up after ART initiation were included. On
the other hand, we excluded HIV patients who had in-
complete baseline records, whose medical charts were
not available during the data collection period and pa-
tients transferred to Debre Markos referral hospital.
Sample size determination and sampling procedures
The minimum required sample size was calculated using a
survival analysis formula. We used a STATATM Version
14.2 statistical software to calculate the sample size by
considering the following assumptions: the level of signifi-
cance (α) = 5%, Za/2 (value at 95% confidence interval =
1.96), power of 80%, and hazard ratio (HR = 2.05 taken
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from a previous study) [26]. We applied the sample size
calculation for each predictor variable, and the one with
the maximum sample size (484) was selected for this
study. Then, we randomly selected 484 HIV-positive pa-
tient records using a computer-generated number among
those initiated treatments from January 30, 2008, to Janu-
ary 26, 2018. To know the final status (event or censored)
of the patient, we followed the selected records for 10
years or until the end of the study period.
Variables
The outcome variable was the time to loss to follow-up,
whereas the predictors were socio-demographic character-
istics (namely, age, sex, marital status, residence, educa-
tional, and occupation). Baseline clinical and laboratory
characteristics (i.e., duration of ART, adherence, drug side
effects, regimen changes, INH prophylaxis, WHO clinical
stage, functional status, baseline CD4 counts, and baseline
ART regimen).
Operational definitions
This study aimed to ascertain the incidence of loss to
follow-up using 10-year data retrieved from medical rec-
ord charts. In this study, loss to follow-up was defined as
not taking ART refill for 3 months or longer from the
last attendance for refill and not yet categorized as dead
or transferred-out [27]. ART adherence was defined as
the percentage of ART drug dosage calculated from a
monthly total dose, and it was classified as good, fair, or
poor. Hence, good adherence was reported if equal to or
greater than 95% or ≤ 3 dose missing per month, fair if
85–94% or 4–8 dose missing per month, or poor if less
than 85% or ≥ 9 dose missing per month [28]. When the
patients missed their ART follow-up for three or longer
appointment months were considered as an event while
those who died during their follow-up, transferred to
other health institutions, and remain on treatment at the
end of the study period were treated as censored. Fur-
thermore, transfer out was considered as clients who
had a transfer letter to initiate ART care and treatment
and need to shift after receiving the service. In this
study, death was ascertained when HIV patients were
documented as death in the ART care and treatment
follow-up sheet by the health care professionals.
Data collection tool and procedure
The data extraction checklist was prepared from the
ART entry and follow-up forms. To ensure data quality,
before data extraction, the data extraction tool was pre-
pared with care from ART intake and follow-up forms.
In addition, we verified consistency between data record-
ing systems and the prepared checklist by randomly
selecting and completing 48 sample chart reviews, which
resulted in slight amendments to the data extraction
checklist. Two BSc nurses who have been working in the
ART clinic of Debre Markos Referral Hospital collected
the data. Two days of training were given for both data
collectors and supervisors to standardize and agree on
the way to review medical records. The supervisor and
principal investigators supervised the data collectors
throughout the entire data collection process.
Data processing and analysis
Data were entered into EpidataTM Version 4.2 and ana-
lyzed using STATA™ Version 14.0 statistical software. At
the end of the data extraction period, the outcome of
each study subject was dichotomized into censored or
event (LTFU). Moreover, to identify the predictor vari-
ables, a cox-proportional hazard regression model was
fitted. To check the assumption of the Cox-proportional
hazard regression model, we used Schoenfeld residual
test for continuous variables and Log-Log plot for cat-
egorical variables.
Furthermore, we checked the model fitness using a
Cox-Snell residual test (see supplementary file fig. 1.).
We used the Nelson-Aalen cumulative hazard curve to
estimate the occurrence of time to loss to follow-up. A
log-rank test was estimated to compare the survival
curves for different categorical explanatory variables.
In univariate analysis, we used the mean with standard
deviations to describe normally distributed continuous
data and median with interquartile range for skewed
continuous data. In another way, the categorical data ex-
tracted from HIV-positive patients were described using
frequency distribution or percentages. Regarding bivari-
able analysis, the outcome variable (loss to follow-up)
and explanatory variables were entered cox-proportional
hazard regression model to select variables for the multi-
variable cox-proportional hazard regression model. As a
result, variables having p value ≤ 0.25 in the bi-variable
analysis were fitted into the multivariable cox-proportion
regression model. Finally, the adjusted hazard ratio with
its corresponding 95% confidence interval (CI) was used
to declare the presence of a significant association be-
tween the explanatory and outcome variables.
Results
Socio-demographic characteristics
About 484 HIV-positive patient record charts were re-
trieved, giving a 100% response rate. The median age of
the study participants was 32 years with an inter-quartile
range (Q1, Q3: 27, 39.5). Two hundred seventy-two
(56.20%) of the study participants were from the urban
residence. The majority, 406 (83.75%) of HIV-positive
patients were married while slightly more than two-thirds
(69.21%) of the study participants attended formal educa-
tion. The majority, 427 (88.41%) of the retrieved HIV-
positive patients’ information were Orthodox Christian by
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religion. During their recruitment for ART, the majority,
420 (86.78%) of the study participants had cell phones.
Slightly more than half, 267 (55.17%) of the participants
had disclosed their serostatus when they were recruited
(Table 1).
Baseline clinical characteristics
Two-hundred ninety-three (60.53%) of the study partici-
pants were WHO clinical stages of III and IV. Regarding
functional status, about three-fourth, 363 (75%) of the
study, participants were experiencing working status.
The median CD4 count was 161 cells/ml with an inter-
quartile range (Q1, Q3: 84, 274.5). Nearly half, 239
(49.38%) of the study participants were taking TDF-
3TC-EFV ART regimen. In terms of nutritional status,
nearly two-thirds, 319 (65.91%), were well nourished
(Table 2).
Follow-up characteristics
This study computed that the median follow-up time for
the included HIV-positive patients 56 months with an
inter-quartile range (Q1, Q3: 12.99, 97.12). The majority
441 (91.12 %) of the participants had a good ART adher-
ence throughout the follow-up period. Almost two-thirds
(67.56%) of the study participants had no experience of
regimens change. Slightly less than one-third, 151
(31.46%) of the study participants had developed tubercu-
losis infection during the follow-up period (Table 3).
Incidence of loss to follow-up
The study participants had 3–120 months follow-up pe-
riods yielding 2294.8 person-years LTFU free time. This
study indicated that the proportion of loss to follow-up
Table 1 Socio-demographic characteristics of HIV-positive adult
individuals on ART at Debre Markos Referral Hospital who were









≥ 45 72 14.88
Education status
Not formally educated* 149 30.79
Primary education 130 26.86
Secondary education 129 26.65



















Table 2 Baseline clinical characteristics of HIV-positive adults on
ART at Debre Markos Referral Hospital who were enrolled from
January 30, 2008, to September 26, 2017
Variables Frequency Percentage
WHO stage
Stage I 117 24.17
Stage II 74 15.29
Stage III 220 45.45






≤ 50 57 11.78
50–150 153 31.61
150–200 65 13.43








Well nourished 319 65.91
Not well nourished 165 34.09
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(LTFU) was 17.36% (n = 84). Similarly, the study re-
vealed that the overall incidence rate of loss to follow-up
(LTFU) was 3.70 (95% CI: 0.03, 0.05) per 100 person-
years. During the 10-year follow-up period, slightly less
than one-third (30.95%) of the HIV-positive patients had
experienced LTFU. The overall incidence rate (Fig. 1),
the incidence rate over residence (Fig. 2), the incidence
rate over ART adherence (Fig. 3), and incidence rate
over median age (Fig. 4) were compared graphically.
Bivariable and multivariable cox-regression analysis
During bivariable cox-regression analysis, nine variables,
namely, baseline regimen, adherence, WHO clinical
stage, residence, having a cell phone, age, baseline CD4
count, experience of TB infection, and experience of
regimen change, were found as a candidate for multivar-
iable cox-regression analysis model.
The final multivariable Cox-regression analysis model
identified that WHO clinical stage IV, rural residence,
and having no cell phones were identified as significant
predictors of LTFU. The model fitness was assessed using
Cox-snell residual test (see supplementary figure 1). The
hazard of loss to follow-up among WHO stage IV HIV pa-
tients was 2.8 times (AHR 2.75; 95% CI 1.23, 6.16) higher
than WHO clinical stage I HIV patients. The hazard of
loss to follow-up among rural residents was decreased by
40% (AHR = 0.60; 95% CI 0.37, 0.99) as compared to
urban residents. Furthermore, the hazard of LTFU among
individuals who had no cell phone was 1.9 times (AHR
1.90; 95% CI 1.14, 3.40) higher as compared to those who
had cell phones (Table 4).
Discussion
Antiretroviral therapy is an intervention to control HIV
infection, improving the quality of life and prolonging
the survival status of HIV patients. So discontinuation of
ART care and treatment threatened the effectiveness of
such intervention [8]. This retrospective cohort study
aimed to determine the incidence and identify predictors
of LTFU among adult HIV patients on ART in Debre
Markos Referral Hospital.
In this study, the overall incidence rate of loss to
follow-up among HIV-positive adults on ART at Debre
Markos Referral Hospital was 3.70 per 100 person-years
of observation. It was lower compared with the study
findings reported in the University of Gondar Teaching
Hospital [14], and Aksum St. Hospital, Ethiopia [14], in
Asian Pacific, India, and South Africa [11, 12, 21]. The
potential elucidation for the disparity might be due to
the difference in the study period, commencing of test
Table 3 Follow-up data of HIV-positive adults on ART at Debre
Markos Referral Hospital who were followed from January 30,
2008, to January 26, 2018
Variables Frequency Percentage















Experience of regimen change
Yes 157 32.44
No 327 67.56








































0 1 2 3 4 5 6 7 8 9 10
Follow-up time in year
Fig. 1 The cumulative hazard rate of lost to ART follow-up among
HIV-positive adult individuals at Debre Markos Referral Hospital,
North-West Ethiopia, from January 30, 2008, to January 26, 2018
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and treat ART initiation criteria, the difference in the
demographic pattern of patients, 1j(TDF-3TC-DTG)
ARV used today instead of 1e(TDF-3TC-EFV), change
in disease staging criteria, the presence of case manager
and adherence supporter and adapting mass laboratory
screening criteria [2, 29, 30]. An improvement on ART
adherence, tracing back of HIV patients who loss there
follow-up to ART, and early initiation of ART have been
adapted recently to get expected clinical outcomes and
improve the quality of life ultimately [31]. Evidence also
suggests that early ART initiation helps to retain HIV-
positive patients on care and treatment [32–34].
In this study, the proportion of HIV patients with clin-
ical stages III and IV were lower (60.53%) than studies
done previously (77.7% and 84%) [14, 15]. Similarly, in this
study, a higher proportion (75%) of the participants were
working in functional status as compared with the previ-
ous studies (50.96% and 64%) [14, 15]. Hence, the differ-
ence in the clinical-stage and functional status might be a
reason for loss to follow-up to be lower in this study [14,
15]. Another possible explanation might relate to patients
experienced less (32.44%) proportion of drug toxicity in
this study as compared with the previous study( 75.5%)
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Fig. 3 The hazard rate of lost to follow-up of HIV-positive adult individuals on ART over their history of ART adherence from January 30, 2008, to
January 26, 2018
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Moreover, the lower incidence rate of loss to
follow-up reported by this study might be due to dif-
ferences in participant’s residence. This means the
proportion of urban residents was only 56.2% in this
study but 96.1% in a previous study [14]. Urban resi-
dents are more prone to self-referral to other health
care facilities and not permanently live in the area,
relatively. This might contribute to the lower rate of
loss to follow-up for this study.
The current study also identified that the WHO clin-
ical stage IV and having no cell phone were found to in-
crease the rate of loss to follow-up.
This study identified WHO clinical stage IV as a pre-
dictor of loss to follow-up from ART care and treatment.
The risk of experiencing loss to follow-up among HIV-
positive patients with WHO clinical stage of IV was 2.8
(AHR 2.75; 95% CI 1.23, 6.16) times higher as compared
with WHO clinical stage I. This finding is in line with
findings reported in Mizan-Tepi University, Oromia Re-
gion, and South Africa [12, 19, 20]. This could be ex-
plained by those HIV-positive patients with WHO
clinical stage IV were highly experienced an immuno-
logical deterioration. Due to this, they could not over-
come the challenge they face in care and treatment and
had discontinued.
Likewise, this study found that the risk of LTFU
among rural residents was reduced by 40% (AHR 0.6;
95% CI 0.37, 0.99) compared with urban residents. It is
in accordance with the study conducted in India [35].
This might be due to patients coming from rural areas
preferred to have ART follow-up in the nearby hospitals.
Because rural residents are stable (permanent residents
relatively), they did not use the self-referral system to
other healthcare institutions due to scarcity of money
and they face less stigma.
Furthermore, ART clients who had no cell phones
were nearly two (AHR 1.90; 95% CI 1.14, 3.40) times
more at risk of experiencing LTFU compared with
their counterparts (having a cell phone). This finding
might be attributable to the cell phone serving as a
means of tracing HIV patients who are on ART. Also,
a cell phone may increase the relationship between
patients and their health professionals. Cell phones
also help to keep an appointment with others and
health facilities’ appointment period. This scenario
compared well with the previous evidence that cell
phone improves health care service delivery processes
by targeting communication between providers and
their patients. Mobile technologies improve clinical
management support in settings where there are no
specialist clinicians, and they can be used to send pa-
tients test results and timely reminders of appoint-
ments [36–38]. Therefore, programmers, communities,
associations, stakeholders, planners, government bod-
ies, and health care professionals need to establish
strategies to provide a cell phone for those HIV-
positive patients with low economic status.
Limitations of the study
As a limitation, this study was not considered some es-
sential predictors, like viral load, liver, and renal function
tests since it was conducted using secondary data that
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Fig. 4 The hazard rate of lost to follow-up of HIV-positive adult individuals on ART over their age categories from January 30, 2008, to January
26, 2018
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Table 4 Multivariable Cox regression analysis of predictors of LTFU among HIV-positive adult subjects on ART at Debre Markos
Referral Hospital, North West Ethiopia, from January 30, 2008, to January 26, 2018
Variables Last status CHR (95% CI) AHR (95% CI) p value
Event Censored
Sex
Male 40 162 1.0 1.0
Female 44 238 0.81 (0.53,1.23) 0.88 (0.54, 1.42) 0.58
ART regimen
1a 8 56 1.0 1.0
1b 13 48 1.6 (0.7, 3.9) 1.6 (0.6, 3.9) 0.37
1c 14 66 1.99 (0.83, 4.8) 2.79 (1.07, 7.23) 0.32
1d 9 31 2.4 (0.94, 6.4) 3.14 (1.13, 8.08) 0.19
1e 40 199 6.7 (3.14, 14.7) 9.3 (3.75 , 23.8) 0.10
History of ART adherence
Poor 23 77 1.0 1.0
Good 61 323 0.5(0.3, 0.8) 1.2(0.3, 0.9) 0.20
WHO clinical stage
Stage I 11 106 1.0 1.0
Stage II 8 66 0.7 (0.29, 0.1.81) 1.09 (0.42, 2.85) 0.45
Stage III 48 172 1.44 (0.75, 2.78) 1.73 (0.87, 3.46) 0.20
Stage IV 17 56 1.8 (0.83, 3.8) 2.75 (1.23, 6.16) 0.01
Residence
Urban 55 217 1.0 1.0
Rural 29 183 0.5 (0.33, 0.8) 0.6 (0.37, 0.99) 0.046
Phone
Yes 68 352 1.0 1.0
No 16 48 1.5 (0.87, 2.6) 1.9 (1.14, 3.4) 0.04
Age categories
15–24 13 40 1.0 1.0
25–34 41 169 0.44 (.22, 0.88) 0.67 (0.35, 1.29) 0.20
35–44 22 127 0.4 (0.22, 0.86) 0.32 (0.15, 0.67) 0.20
≥ 45 8 64 0.4 (0.17, 0.99) 0.33 (0.13, 0.83) 0.19
Baseline CD4 Count
≤ 50 11 46 1.0 1.0
50–150 28 125 0.68 (0.34, 1.37) 0.76 (0.37, 1.57) 0.46
150–200 12 53 0.58 (0.26, 1.33) 0.52 (0.21, 1.28) 0.16
≥ 200 33 176 1.14 (0.57, 2.27) 0.68 (0.32, 1.43) 0.31
History of TB infection
No 56 273 1.0 1.0
Yes 25 126 0.58 (0.36, 0.94 0.74 (0.43, 1.26) 0.27
History of ART regimen change
No 54 273 1.0 1.0
Yes 30 127 0.72 (0.46, 1.14) 1.59 (0.9, 2.8) 0.11
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lead to underestimating the incidence rate of loss to
follow-up owing to record problems.
Conclusion
This study revealed that the incidence rate of loss to
follow-up among adult HIV-positive patients at Debre
Markos Referral Hospital was low. Having no cell phone,
WHO clinical stage IV, and rural residence were the
identified predictors of loss to follow-up. Therefore, pro-
gram leaders and initiatives should strengthen early initi-
ation (WHO clinical stage I) of ART care and treatment.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s41182-020-00266-z.
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